Sutro Biopharma Inc.'s deal with Merck & Co. Inc. puts $60 million in the bank immediately and could garner as much as $1.6 billion more in milestone payments as the companies put Sutro's cell-free protein synthesis and site-specific conjugation platforms to work in a bid for immune-modulating cytokine derivatives targeting oncology and autoimmune indications.